Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Endocrine 1

Conditions

Uterine Cervical Neoplasms 1Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Neuroendocrine 1

Interventions

Trastuzumab 2Magnetic Resonance Spectroscopy 2Fluorodeoxyglucose F18 2FAPI-46 2tipifarnib 1temsirolimus 1pembrolizumab 1milademetan 1entinostat 1berzosertib 1Vinorelbine 1Topotecan 1Sirolimus 1Ritonavir 1Radiotherapy 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Interleukin-12 Subunit p35 1Interleukin-12 1Indinavir 1Immunotherapy 1Fentanyl 1Drug Therapy 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × berzosertib × Endocrine × Clear all
NCT02487095 2025-04-13

Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
62 enrolled 29 charts
EndocrineGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡